ERIS

What Eris Lifesciences promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 27 tracked 1 delivered 8 missed 18 open
  • Consolidated EBITDA Margin delivered said Q2 FY25 Promised: 35% for FY25 Q1 FY27: Target period passed.
  • DBF Revenue missed said Q2 FY25 Promised: ₹2,600 crores for FY25 Q1 FY27: Target period passed.
  • CDMO Revenue at risk said Q1 FY26 Promised: ₹100 crores revenue for FY27 Q1 FY27: Management states CAPA actions for EU GMP are on track for sites to be audit-ready by Dec 2026. However, FY27 export guidance is now 'flattish', reinforcing the significant risk to this revenue target.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 27 tracked commitments for Eris Lifesciences — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens